ClinicalTrials.Veeva

Menu

Bioequivalence of Dotilavir Sodium Tablets in Healthy Subjects in the Fasting and Fed State

Q

Qingdao University

Status and phase

Unknown
Phase 1

Conditions

Healthy Volunteers

Treatments

Drug: Dotilavir sodium tablet
Drug: Dotilavir sodium tablet(Tivicay@)

Study type

Interventional

Funder types

Other

Identifiers

NCT05168176
QL-YK1-045-001

Details and patient eligibility

About

The primary purpose of this study is to evaluate the bioequivalence of two dotilavir sodium tablets in the fasting and fed state. The secondary purpose of this study is to observe the safety of the test and reference preparations. An open-label, randomized, single-dose, crossover study in healthy Chinese volunteers was performed. A single oral dose of 50 mg of two dotilavir sodium tablets was administered to 64 healthy volunteers, with 36 in the fasted group and 28 consuming a high-fat diet. The evaluated pharmacokinetic parameters, including maximum concentration (Cmax), the area under the concentration-time curve (AUC0-t and AUC0-∞) were assessed for bioequivalence.

Enrollment

64 estimated patients

Sex

All

Ages

18+ years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  • Healthy male or female subjects ≥18 years of age, with appropriate sex ratio
  • The body mass index is in the range of 19.0-27.0 kg/m2 (including the critical value). The weight of male is not less than 50.0 kg, and that of female is not less than 45.0 kg
  • The subjects have no family planning within 3 months and could select contraceptive method.
  • Before the study, all subjects have been informed of the study's purpose, protocal, benefits, and risks, and signed the informed consent voluntarily

Exclusion criteria

  • Subjects with allergic constitution.
  • Being allergy to the study medications, smoking, alcohol abuse.
  • Participation in another clinical trial within 3 months.
  • Blood donation, massive blood loss (#400mL) or enrolled in other clinical trials 3 months prior to screening;
  • Hepatitis (including hepatitis B and C), positive screening results for AIDS or syphilis;

Trial design

Primary purpose

Other

Allocation

Randomized

Interventional model

Crossover Assignment

Masking

None (Open label)

64 participants in 2 patient groups

Dotilavir sodium tablet
Experimental group
Treatment:
Drug: Dotilavir sodium tablet
Dotilavir sodium tablet(Tivicay@)
Active Comparator group
Treatment:
Drug: Dotilavir sodium tablet(Tivicay@)

Trial contacts and locations

1

Loading...

Central trial contact

yu Cao, doctor

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems